• Program Management for Medical Affairs (MA) Immunology Respiratory & GI TAs, across 3 approved (Asthma, CRSwNP, EOE) & 2 unapproved indications (COPD, Dupilumab & Itepekimab), advising 2 TA heads, 8 Medical Directors and 2 Field Medical National Directors• Led development of annual Global & US Alliance (Regeneron & Sanofi) Strategic Medical Plans for Asthma, CRSwNP, COPD & EoE• Drove alignment on Global & US Alliance Strategic Medical Plans through implementation of planning workshops & close partnership with 5 TA Heads, 22 Indication Lead Medical Directors, 4 Field Medical National Directors & additional cross-functional teams• Created tactical plan harmonized to Alliance Strategic Medical Plans for Dupilumab Immunology (Derm, Resp, GI) & steered functional leads on corresponding budget request • Negotiated budget requests across Alliance to provide unified finance deliverable• Managed annual Immunology program budget (> $300M) inception to execution, driving fiscal accountability • Monitored, tracked & reported on the execution of > 100 tactics to support annual program goal of executing on time & on strategy, within 3% of approved budget• Coordinated governance reviews of 16 Phase IV studies, liaising with key stakeholders• Provided direction on content development & delivery to medical leads in support of study reviews• Proposed meeting content to satisfy knowledge gaps & identify areas of opportunity for key meetings• Moderated key company & alliance meetings to ensure achievement of objectives (e.g. Medical Impact Team, US Alliance Team, Operational Meeting, Joint Medical Affairs Strategy Team) • Partnered with MA Leads to report status, resolve issues & implement risk mitigation across medical functions (e.g. Med Ed, Med Ops, HEOR, Med Info, Pubs)• Evaluated critical areas of opportunity to implement process streamlining & adoption of best practices (e.g. advisory board planning, congress approval workflows, IIS reviews)

• Managed closeout activities for 32 investigator initiated studies (IIS); 26 studies closed in 2021• Developed study closure guidance & tools for medical study operations team to utilize• Managed data sharing review process for data transparency• Coordinated Joint Medical Affairs Committee review process; 92 studies reviewed in 2021• Facilitated study start-up activities for 17 IIS; liaised between sponsor & company legal department, collected essential documents, performed compliance checks, oversaw initial drug supply & distribution to sites• Supported IIS through active enrollment phase (monthly outreach, study timeline tracking & reforecasting, coordinating drug supply, processing temperature excursions)• Collaborated with PV team to implement quarterly SAE reconciliations for IIS• Liaised with clinical operations team to provide drug forecasts for upcoming & active IIS• Provided annual & quarterly budget forecasts for active IIS• Key contributor to Safety Portal development; responsible for ensuring IIS sponsor compliance with user requirements; secured confidentiality agreements between Regeneron & 35 sponsor sites in time for safety portal launch • Performed monthly investigator alert letter reconciliations & managed safety portal distribution list• Provided Medical Study Operations user feedback for submission portal development/refinement• Refined tracking tool to include capability for reporting timeline metrics in real time• Provided metrics for volume of IIS submissions, reviews, approvals & activated studies for all TAs• Collaborated with field medical team to implement proactive review tracking action items to facilitate adherence to accelerated review timelines necessary for meeting team goals• Organized & facilitated committee meetings; distributed agendas & minutes; collected votes• Ensured timely internal review & tracking of IIS sponsor publications• Standardized trackers in anticipation of data management system launch

Personal Training Services

Conducted primary neuron dissociation and studied the ventral tegmental area of rats.

Assisted with various cognitive experiments.